NCT00084279View on ClinicalTrials.gov

CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

April 30, 2006

Conditions

Chronic Hepatitis C

Interventions

DRUG

Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin

interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily

Trial Locations (1)

94005

InterMune, Inc., Brisbane